tiprankstipranks
Advertisement

HDEF - ETF AI Analysis

Compare

Top Page

HDEF

Xtrackers MSCI EAFE High Dividend Yield Equity ETF (HDEF)

Rating:68Neutral
Price Target:
HDEF, the Xtrackers MSCI EAFE High Dividend Yield Equity ETF, earns a solid overall rating thanks to high-quality, income-focused holdings like Novartis, which combines strong profitability, a stable balance sheet, and solid dividend support, and TotalEnergies, which adds attractive valuation, positive earnings sentiment, and supportive technical trends. Other large positions such as Nestlé, Roche, and Sanofi further strengthen the fund with robust cash flows and generally sound fundamentals, though some names like Allianz and Unilever face weaker technical momentum or valuation concerns. The main risk is that many top holdings are concentrated in similar international dividend-heavy sectors, so shifts in global sentiment toward these areas could affect the ETF as a whole.
Positive Factors
Low Expense Ratio
The fund charges a relatively low fee, which helps investors keep more of their returns over time.
Broad International Diversification
Holdings spread across many developed markets such as the UK, Switzerland, France, Germany, and Japan help reduce reliance on any single country.
Solid Recent Performance
The ETF has shown steady gains over the past month, three months, and year to date, indicating recent positive momentum.
Negative Factors
Concentration in a Few Countries
A large share of assets is focused in just a handful of markets like the UK and Switzerland, which can increase country-specific risk.
Mixed Performance Among Top Holdings
Several major positions, including Roche, Nestlé, Unilever, British American Tobacco, and Zurich Insurance Group, have shown weak or negative performance, which can drag on overall returns.
Limited Technology Exposure
Very small allocation to the technology sector means investors may miss out if tech stocks continue to be strong drivers of global market growth.

HDEF vs. SPDR S&P 500 ETF (SPY)

HDEF Summary

HDEF is an ETF that follows the MSCI EAFE High Dividend Yield Index, focusing on companies in developed markets outside the U.S. and Canada, such as the UK, Switzerland, Japan, and Europe. It holds many well-known, established businesses like Shell, Novartis, Nestlé, and Unilever that tend to pay relatively high dividends. Someone might invest in HDEF to seek regular income and diversify their portfolio internationally, instead of owning only U.S. stocks. A key risk is that the fund’s value and dividend payments can go up and down with global stock markets and foreign economies.
How much will it cost me?The expense ratio for HDEF is 0.09%, which means you’ll pay $0.90 per year for every $1,000 invested. This is lower than average because HDEF is passively managed, tracking an index rather than relying on active stock selection.
What would affect this ETF?HDEF could benefit from stable dividend payouts and growth in developed markets outside North America, especially if sectors like financials and healthcare, which have significant weight in the ETF, perform well. However, challenges such as rising interest rates, economic slowdowns in Europe or Asia, or regulatory changes affecting top holdings like Novartis or Shell could negatively impact returns. Diversification across sectors and regions provides some resilience, but global economic conditions remain a key factor to watch.

HDEF Top 10 Holdings

HDEF leans heavily on Europe’s dividend stalwarts, with energy and health care setting the tone. TotalEnergies has been one of the fund’s main engines lately, while Shell’s earlier strength is now looking a bit tired. In health care, Novartis is quietly rising, but Roche has been more mixed, limiting its boost. On the defensive side, Nestlé is steady but not exciting, and Unilever has been dragging the consumer bucket. Overall, this is a developed-markets ex-North America play, anchored in European blue chips rather than fast-growth tech names.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Shell (UK)5.37%$121.79M£184.86B32.32%
73
Outperform
Roche Holding AG5.31%$120.51M$327.04B22.13%
73
Outperform
Novartis AG5.23%$118.76MCHF207.57B22.14%
80
Outperform
Nestlé SA4.73%$107.41MCHF205.30B-1.29%
71
Outperform
TotalEnergies SE4.54%$103.03M€164.70B45.23%
78
Outperform
Allianz4.40%$99.88M€146.93B7.31%
67
Neutral
Iberdrola3.83%$86.90M€133.09B29.16%
67
Neutral
British American Tobacco3.17%$72.00M£93.11B34.43%
71
Outperform
Unilever3.17%$71.97M£93.54B
72
Outperform
Sanofi2.58%$58.52M€96.41B-9.93%
75
Outperform

HDEF Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
32.67
Positive
100DMA
32.06
Positive
200DMA
30.67
Positive
Market Momentum
MACD
0.10
Positive
RSI
54.30
Neutral
STOCH
52.71
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HDEF, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 32.99, equal to the 50-day MA of 32.67, and equal to the 200-day MA of 30.67, indicating a bullish trend. The MACD of 0.10 indicates Positive momentum. The RSI at 54.30 is Neutral, neither overbought nor oversold. The STOCH value of 52.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HDEF.

HDEF Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$2.30B0.09%
68
Neutral
$8.32B0.50%
59
Neutral
$2.43B0.09%
66
Neutral
$1.35B0.55%
59
Neutral
$682.33M0.58%
62
Neutral
$45.83M0.55%
56
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HDEF
Xtrackers MSCI EAFE High Dividend Yield Equity ETF
33.02
5.70
20.86%
IDV
iShares International Select Dividend ETF
DIVI
Franklin LibertyQ International Equity Hedged ETF
FGD
First Trust Dow Jones Global Select Dividend Index Fund
DTH
WisdomTree International High Dividend Fund
EFAS
Global X MSCI SuperDividend EAFE ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement